Affiliation:
1. Russian Medical Academy of Continuing Professional Education
2. I.M. Sechenov First Moscow State Medical University (Sechenov University)
Abstract
Aim. To summarize Russian studies using pharmacogenetic testing as applied to cardiology.Material and methods. The authors conducted an online search for articles in December 2018 using the following databases: PubMed, Google Scholar, eLIBRARY. The search was carried out by keywords: "Russia", "Russian", "cardiology" together with the terms associated with the polymorphic marker, including: «P450», «CYP2C19», «CYP2D6», «CYP2B1», «CYP2B6», «CYP2Е1», «CYP2C8», «CYP2C9», «CYP3A4», «CYP3A5», «CYP1A1», «CYP1A2», «CYP4F2», «CYP4F1», «ABCB1», «SLCO1B1», «VKORC1», «GGCX», «SULT1A1», «CULT1», «CES1», «gene», «genes», «pharmacogenetics», «pharmacogenomics», «ethnic group».Results. Generalization of information allowed to identify obscure genes that need to be investigated in pharmacogenetic studies. This information can be used for the development of dosing algorithms and the priority choice of drugs, considering the results of pharmacogenetic testing and planning future research.Conclusion. The results of the literature review indicate the importance of studying the most clinically valid and clinically useful pharmacogenetic markers (CYP2C19, CYP2C9, VKORC1, SLCO1B1) among various ethnic groups in the Russian Federation. With the accumulation of evidence of clinical validity and clinical utility of other pharmacogenetic markers (CES1, CYP2D6*4, etc.), the problem of interethnic differences in the carriage of clinically significant polymorphisms of these genes identified in previous studies in the Russian Federation increasingly requires attention. The most promising for the introduction into the clinical practice in the Russian Federation in the near future are polymorphic markers of the CYP2C19, CYP2C9, VKORC1 and SLCO1B1 genes.
Publisher
Stolichnaya Izdatelskaya Kompaniyaizdat
Subject
Pharmacology (medical),Cardiology and Cardiovascular Medicine
Reference78 articles.
1. Order of the Ministry of Health of the Russian Federation of April 24, 2018 N 186 “On approval of the Concept of predictive, preventive and personalized medicine”. [cited by May 18, 2019]. Available from: www.garant.ru/products/ipo/prime/doc/71847662. (In Russ.)
2. GKS. All-Russian population census 2010. The national composition of the population of Russia 2010. [cited by May 18, 2019]. Available from: www.gks.ru/free_doc/new_site/perepis2010/croc/perepis_itogi1612.htm. (In Russ.)
3. Ferranti J., Horvath M., Cozart H., et al. A Multifaceted Approach to Safety. Journal of Patient Safety. 2008;4(3):184-90. DOI:10.1097/PTS.0b013e318184a9d5.
4. Pirmohamed M., Park B. Adverse drug reactions: back to the future. British Journal of Clinical Pharmacology. 2003;55(5):486-92. DOI:10.1046/j.1365-2125.2003.01847.x.
5. Jha A., Kuperman G., Teich J., et al. Identifying Adverse Drug Events: Development of a Computerbased Monitor and Comparison with Chart Review and Stimulated Voluntary Report. Journal of the American Medical Informatics Association. 1998;5(3):305-14. DOI:10.1136/jamia.1998.0050305.
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献